Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aligos Therapeutics ( (ALGS) ) has shared an announcement.
On April 14, 2026, Aligos Therapeutics reported first interim analysis results from its Phase 2 B-SUPREME trial of pevifoscorvir sodium in adults with chronic hepatitis B virus infection, showing that the independent safety board recommended continuing the HBeAg- cohort and increasing its sample size from 74 to 100 participants after futility criteria were not met. Study drugs were well tolerated with no clinically concerning safety signals or viral breakthrough observed among 174 participants reviewed, enrollment completion for the HBeAg- cohort is expected in the second half of 2026, and the company reiterated guidance for a second interim analysis in late 2026 and topline data in 2027.
Aligos also disclosed that the U.S. Food and Drug Administration granted Fast Track Designation to pevifoscorvir sodium, an oral capsid assembly modulator being developed as a potential best- or first-in-class treatment for chronic hepatitis B virus infection. The designation, supported by 96-week Phase 1 data showing sustained viral marker reductions and favorable tolerability, underscores the drug’s potential to address significant unmet need in HBV and could accelerate its regulatory path, reinforcing Aligos’s positioning in the competitive liver disease therapeutics space.
The most recent analyst rating on (ALGS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.
Spark’s Take on ALGS Stock
According to Spark, TipRanks’ AI Analyst, ALGS is a Neutral.
The score is mainly held down by very weak financial performance (zero revenue in 2025, persistent losses, and heavy cash burn) and a bearish technical setup (below key moving averages with negative MACD). Valuation offers limited support due to ongoing losses and no dividend, while the leadership/accounting appointment is a modest positive but not enough to offset the core fundamentals.
To see Spark’s full report on ALGS stock, click here.
More about Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for liver and viral diseases, including chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity and coronaviruses. The South San Francisco-based company applies a science-driven approach and deep R&D expertise to advance a pipeline targeting high unmet medical needs in these indications.
Average Trading Volume: 50,827
Technical Sentiment Signal: Sell
Current Market Cap: $49.47M
Find detailed analytics on ALGS stock on TipRanks’ Stock Analysis page.